The Unapproved Fixed-Dose Combination Drugs in India: A Public Health Concern

By Staff Writer

November 25, 2023

The Ongoing Issue of Unapproved Fixed-Dose Combination Drugs in India

The regulation of medicines in India, a responsibility shared between the central government and individual states, has been a source of friction and calls for reform. One area of notable concern has been the regulation of Fixed-Dose Combination drugs (FDCs), specifically antibiotic FDCs. Despite regulatory initiatives since 2007, hundreds of unapproved antibiotic FDC formulations remained on the Indian market, Accounting for over 700 million of the 4.5 billion standard units sold in 2020. This issue extends beyond India’s borders, contributing to the global concern of increasing antimicrobial resistance.

The Impact on Public Health and Global Concerns

India’s vast sales of centrally unapproved FDCs pose a significant public health concern. This concern escalates when considering the context of increasing antimicrobial resistance. In 2020, 41.5% of the 4.5 billion standard units of antibiotic FDCs sold were attributed to combinations listed as ‘not recommended’ by WHO. The limited progress in controlling these FDCs is a result of weak, convoluted, and inefficient regulatory enforcement.

Recommendations and Further Steps

Regular surveillance of the market, informed regulatory enforcement, and antimicrobial stewardship are recommended. Criminal proceedings should be considered against manufacturers of the formulations marketed without a record of prior Central Drugs Standard Control Organisation (CDSCO) approval. The prescription of only well-evidenced FDCs, such as those listed in National List of Essential Medicines (NLEM), would reduce the use of FDCs and facilitate antimicrobial stewardship. Further research is needed on the control measures and trends in sales of FDCs in other therapeutic areas.

Reference url

Recent Posts

Zimislecel type 1 diabetes
   

Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential

🚀 What if we could revolutionize Type 1 diabetes treatment?

Vertex Pharmaceuticals has made significant strides with its promising phase 1/2 trial results for **zimislecel**, a stem cell-derived therapy that not only restores insulin production but also drastically reduces severe hypoglycemic events. As phase 3 trials commence, this breakthrough could reshape care for T1D patients and potentially reduce long-term healthcare costs.

Curious to learn how zimislecel and other potential cell therapies may redefine diabetes management? Click to read more!

#SyenzaNews #biotechnology #HealthEconomics

biosimilar clinical approach
    

Biosimilar Clinical Approach

🚀 How is the EMA’s new biosimilar clinical approach changing the landscape of drug approvals in Europe?

With a focus on tailored clinical assessments, the EMA is streamlining the pathway for biosimilars by allowing analytical data to take precedence over large-scale comparative efficacy studies. This shift promises to enhance patient access to life-saving therapies while maintaining rigorous safety standards.

Dive deeper into the implications of this innovative regulatory approach and find out how it can impact health economics and market access.

👉 Read more in the full article!
#SyenzaNews #regulatoryaffairs #MarketAccess

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.